“Pemivibart has now demonstrated antiviral activity in neutralization assays representing thirty-nine distinct SARS-CoV-2 variants across almost three years of rapid virus evolution. The ongoing ...
The samples were tested for a wide range of respiratory pathogens, including HMPV, COVID-19, influenza viruses, respiratory syncytial virus (RSV), adenovirus, rhinovirus, enterovirus and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback